Trade Summary

Yesterday, Hopkinson Craig C., serving as EVP R&D, Chief Medical Officer at Alkermes plc. (ALKS), sold 9,000 shares at $48.58 per share, for a total transaction value of $437,220.00. Following this transaction, Hopkinson Craig C. now holds 69,389 shares of ALKS.

This sale represents a 11.48% decrease in Hopkinson Craig C.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, August 3, 2026 and publicly disclosed via SEC Form 4 filing on Monday, August 3, 2026 at 7:12 PM ET, meaning the disclosure happened on the same day as the trade.

Alkermes plc. operates in the HEALTHCARE sector, specifically within the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.